{"id":4884,"date":"2026-07-01T17:32:17","date_gmt":"2026-07-01T14:32:17","guid":{"rendered":"https:\/\/staging.iasispharma.com\/en\/?p=4884"},"modified":"2026-10-30T13:29:41","modified_gmt":"2026-10-30T11:29:41","slug":"new-product-launch-announcement-sitagliptiniasis-25-mgml-oral-solution","status":"publish","type":"post","link":"https:\/\/iasispharma.com\/en\/all-articles\/new-product-launch-announcement-sitagliptiniasis-25-mgml-oral-solution\/","title":{"rendered":"NEW PRODUCT LAUNCH ANNOUNCEMENT: Sitagliptin\/IASIS 25 mg\/mL oral solution"},"content":{"rendered":"<h3><strong>An Innovative, Important &amp; Unique Prescribing Option for Improving Glycemic Control in Type 2 Diabetes Mellitus<\/strong><\/h3>\n<p><strong>IASIS PHARMA<\/strong> is pleased to announce the launch of <strong>Sitagliptin\/IASIS 25 mg\/mL<\/strong> in the pharmaceutical form of an <strong>oral solution<\/strong>.<\/p>\n<p>This is a new, innovative, and unique formulation belonging to the class of DPP-4i. It is an R&amp;D and manufacturing product by <strong>IASIS PHARMA HELLAS<\/strong>.<\/p>\n<p>Each 1 mL of <strong>Sitagliptin\/IASIS<\/strong> oral solution contains sitagliptin hydrochloride monohydrate, equivalent to 25 mg of sitagliptin.<\/p>\n<h3><strong>Superior to Solid Dosage Forms &amp; Optimal Adhearence<\/strong><strong>:<\/strong><\/h3>\n<p><strong>Sitagliptin\/IASIS 25 mg\/mL<\/strong> oral solution represents an excellent therapeutic option, specifically designed for patients facing swallowing difficulties (dysphagia). It provides patients with type 2 diabetes mellitus with rapid bioavailability, high dosing accuracy, ease of titration, and optimal treatment compliance.<\/p>\n<h3><strong>Dosage and Administration :<\/strong><\/h3>\n<p>The recommended dose is 100 mg (corresponding to <strong>4 mL of oral solution<\/strong>) of sitagliptin once daily, taken with or without food. The solution is slightly opalescent, off-white, featuring a pleasant wild berry aroma.<\/p>\n<h3><strong>Suitable for Special Patient Populations (Renal Impairment)<\/strong><strong>:<\/strong><\/h3>\n<p>According to the Summary of Product Characteristics (SPC), no dose adjustment is required for patients with mild or moderate renal impairment (GFR \u2265 45 mL\/min). For patients with GFR \u2265 30 to &lt; 45 mL\/min, the dose is adjusted to 50 mg (2 mL of solution) once daily, while for severe renal impairment (GFR &lt; 30 mL\/min), the dose is 25 mg (1 mL of solution) once daily.<\/p>\n<h3><strong>Packaging &amp; Ease of Use:<\/strong><\/h3>\n<p><strong>Sitagliptin\/IASIS<\/strong> is supplied in an amber glass bottle. To ensure maximum dosing accuracy and convenience during administration, <strong>the pack includes a 5 mL graduated plastic syringe in 0.5 mL increments<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>An Innovative, Important &amp; Unique Prescribing Option for Improving Glycemic Control in Type 2 Diabetes Mellitus IASIS PHARMA is pleased to announce the launch of Sitagliptin\/IASIS 25 mg\/mL in the pharmaceutical form of an oral solution. This is a new, innovative, and unique formulation belonging to the class of DPP-4i. It is an R&amp;D and  [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":4879,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[33,145,146,147,154],"tags":[],"class_list":["post-4884","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-articles","category-company-news","category-product-launches","category-research-development","category-research-and-development-projects-en"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7HJeP-1gM","jetpack_featured_media_url":"https:\/\/iasispharma.com\/wp-content\/uploads\/2026\/07\/Box_Sitagliptin.png","_links":{"self":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts\/4884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/comments?post=4884"}],"version-history":[{"count":1,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts\/4884\/revisions"}],"predecessor-version":[{"id":4885,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts\/4884\/revisions\/4885"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/media\/4879"}],"wp:attachment":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/media?parent=4884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/categories?post=4884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/tags?post=4884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}